ASTRAZENECA (AZN) Company Report

Analyst Coverage

Research analysts who have asked questions during ASTRAZENECA earnings calls.

Luisa Hector

Berenberg

6 questions for AZN

Also covers: ABBV, BMY, MRK +1 more

Rajan Sharma

Goldman Sachs Group, Inc.

6 questions for AZN

Also covers: ARGX, AUTL, CVAC +6 more

Sachin Jain

Bank of America

6 questions for AZN

Also covers: GMAB, GSK, NVO +2 more

Gonzalo Artiach

Danske Bank

5 questions for AZN

Matthew Weston

UBS Group AG

5 questions for AZN

Also covers: GSK, NVS, SNY

Mattias Häggblom

Handelsbanken

5 questions for AZN

Also covers: GNNDY

Peter Verdult

Citigroup Inc.

5 questions for AZN

Also covers: EVO, GMAB, GRFS +4 more

Seamus Fernandez

Guggenheim Partners

5 questions for AZN

Also covers: AMLX, ARCT, ARQT +9 more

James Gordon

JPMorgan Chase & Co.

4 questions for AZN

Also covers: ARGX, GRFS, GSK +1 more

Justin Smith

Bernstein

4 questions for AZN

Also covers: GSK, SCWO

Sarita Kapila

Morgan Stanley

4 questions for AZN

Also covers: GSK, SNY

Simon Baker

Redburn Atlantic

4 questions for AZN

Also covers: AUTL, BNTX, GILD +5 more

Steve Scala

Cowen

4 questions for AZN

Also covers: ABBV, BMY, GSK +6 more

Michael Leuchten

Jefferies

3 questions for AZN

Also covers: GSK, NVO, NVS +1 more

Richard Vosser

JPMorgan Chase & Co.

2 questions for AZN

Also covers: ARGX, MOLN, NVO +2 more

Emily Field

Barclays

1 question for AZN

Also covers: GMAB, GSK, NVO +2 more

Emmanuel Papadakis

Deutsche Bank

1 question for AZN

Also covers: NVO, NVS, SNY

Eric Le Berrigaud

Stifel

1 question for AZN

Also covers: NVS, SNY

Jo Walton

UBS

1 question for AZN

Also covers: GSK, NVO, NVS +1 more

Mark Purcell

Morgan Stanley

1 question for AZN

Also covers: GSK, NVS

Peter Welford

Jefferies

1 question for AZN

Also covers: GSK, NVO, NVS +1 more

Rajesh Kumar

HSBC

1 question for AZN

Also covers: BZLFY, LLY, NVO +2 more

Richard Parkes

BNP Paribas Exane

1 question for AZN

Also covers: GSK, NVO, NVS

Timothy Anderson

BofA Securities

1 question for AZN

Also covers: ABBV, AMGN, BIIB +10 more

Latest news

Recent press releases and 8-K filings for AZN.

AstraZeneca Provides Update on Saphnelo Subcutaneous Administration US Regulatory Review

AZN

Product Launch

Guidance Update

The US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for Saphnelo (anifrolumab) for subcutaneous administration in adult patients with systemic lupus erythematosus (SLE).
AstraZeneca has since provided the requested information to the FDA, with a decision on the updated application expected in the first half of 2026.
While the US subcutaneous application is pending, intravenous (IV) Saphnelo remains commercially available, and the subcutaneous formulation was approved in the European Union (EU) in December 2025.
AstraZeneca will pay Bristol-Myers Squibb (BMS) a mid-teens royalty for US sales of Saphnelo under an updated 2025 agreement.

16 hours ago

6-K

AstraZeneca's Imfinzi Recommended in EU for Early Gastric Cancer

AZN

Product Launch

New Projects/Investments

AstraZeneca's Imfinzi (durvalumab) in combination with FLOT chemotherapy has been recommended for approval in the EU by the CHMP for adult patients with resectable, early-stage and locally advanced gastric and gastroesophageal junction (GEJ) cancers.
This recommendation is based on the MATTERHORN Phase III trial, which demonstrated a 29% reduction in the risk of disease progression, recurrence or death and a 22% reduction in the risk of death for the Imfinzi regimen compared to chemotherapy alone.
If approved, this would be the first immunotherapy-based perioperative therapy for patients in this setting in the EU.
Imfinzi is already approved in the US and other countries for this same indication based on the MATTERHORN results.

1 day ago

6-K

AstraZeneca Begins Trading Ordinary Shares on NYSE

AZN

Delisting/Listing Issues

Guidance Update

AstraZeneca commenced trading its ordinary shares on the New York Stock Exchange (NYSE) on February 2, 2026, to provide broader access for US investors.
This move harmonizes the trading of AstraZeneca ordinary shares across the NYSE, London Stock Exchange (LSE), and Nasdaq Stockholm (STO) under the ticker symbol "AZN".
The prior listing of American Depositary Shares and US dollar bonds on Nasdaq ceased on January 30, 2026.
AstraZeneca aims to grow annual revenue to $80 billion and launch 20 new medicines by 2030.

1 day ago

6-K

AstraZeneca Announces Strategic Partnership with CSPC Pharmaceuticals

AZN

M&A

New Projects/Investments

AstraZeneca has entered into a strategic collaboration agreement with CSPC Pharmaceuticals to enhance its weight management portfolio for obesity and type 2 diabetes.
The agreement includes eight programmes, granting AstraZeneca exclusive global rights outside of China to CSPC's once-monthly injectable weight management portfolio, which features a clinical-ready asset, SYH2082.
AstraZeneca will make an upfront payment of $1.2 billion to CSPC, with potential development and regulatory milestones of up to $3.5 billion across all programmes, in addition to commercialisation and sales milestones plus tiered royalties.
The collaboration provides AstraZeneca access to CSPC's advanced AI-driven peptide drug discovery platform and proprietary LiquidGel once-monthly dosing platform technology.
The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions and regulatory clearances.

5 days ago

6-K

AstraZeneca announces $15 billion investment in China through 2030

AZN

New Projects/Investments

Hiring

AstraZeneca plans to invest $15 billion in China through 2030 to expand medicines manufacturing and R&D, focusing on pioneering next-generation innovative medicines.
This investment will enhance AstraZeneca's R&D footprint and develop existing manufacturing facilities in China, with the goal of growing its highly skilled workforce in the country beyond 20,000.
China is AstraZeneca's second-largest market and a strategic hub for global innovation, currently employing over 17,000 people in the country.

6 days ago

6-K

AstraZeneca Reports Strong 9M 2025 Performance and Reaffirms 2030 Ambition

AZN

Guidance Update

New Projects/Investments

Revenue Acceleration/Inflection

AstraZeneca reported strong commercial performance for the first nine months of 2025, with total revenue increasing by 11% and core EPS growing 15%.
The company reiterated its four-year guidance for total revenue to increase by high single digits and core EPS by low double-digit % at constant exchange rates, expressing high confidence in reaching its $80 billion ambition by 2030.
AstraZeneca achieved 16 positive phase 3 readouts since fiscal 2024 results, including FDA approvals for Imfinzi and HER2, and priority review for Baxdrostat with a PDUFA date in Q2 2026.
Anticipated Q4 2025 headwinds include VBP and year-end hospital order dynamics in China, tender offer timings in emerging markets, and a comparison impact from over $800 million in sales-based milestones booked in Q4 2024.

Jan 13, 2026, 5:00 PM

Transcript

AstraZeneca Reports Strong 9M 2025 Performance and Pipeline Progress

AZN

Guidance Update

New Projects/Investments

Product Launch

AstraZeneca reported strong commercial performance for the first nine months of 2025, with total revenue up 11% and core EPS growing 15%, and reiterated its four-year guidance for total revenue and core EPS to increase by high single digits and low double-digit % respectively at constant exchange rates. The company anticipates fourth-quarter 2025 headwinds and noted that over $800 million in sales-based milestones booked in Q4 2024 will affect year-over-year comparison.
The company achieved 16 positive Phase 3 readouts since fiscal 2024 results, including recent FDA approvals for Imfinzi and Enhertu, and a priority review for baxdrostat with a PDUFA date in Q2 2026. AstraZeneca plans to launch baxdrostat, camizestrant, and garadacimab in 2026 and will start Phase 3 trials for its dual CD19 BCMA CAR-T therapy, AZD0120, in multiple myeloma this year.
AstraZeneca remains confident in reaching its $80 billion revenue ambition in 2030 and anticipates full-year 2026 R&D costs to be towards the upper end of the low 20s % range of total revenue.

Jan 13, 2026, 5:00 PM

Transcript

AstraZeneca Reports Strong 2025 Performance and Confident 2030 Outlook

AZN

Guidance Update

Product Launch

New Projects/Investments

AstraZeneca reported strong commercial performance in the first nine months of 2025, with total revenue up 11% and core EPS growing 15%.
The company reiterated its four-year guidance for total revenue to increase by high single digits and core EPS by low double-digit % at constant exchange rates, expressing increased confidence in achieving its $80 billion revenue ambition by 2030.
AstraZeneca anticipates fourth-quarter 2025 headwinds in China and certain emerging markets, and noted that over $800 million in sales-based milestones booked in Q4 2024 will impact year-over-year comparisons.
The company expects full-year 2026 R&D costs to be at the upper end of the low 20s % range of total revenue and plans for multiple high-value phase 3 readouts in 2026.
Recent regulatory successes include FDA approvals for Imfinzi in perioperative gastric cancer and HER2 in first-line HER2-positive breast cancer in late 2025, and Baxdrostat was accepted for priority review with a PDUFA date in Q2 2026.

Jan 13, 2026, 5:00 PM

Transcript

AstraZeneca's Enhertu Receives Breakthrough Therapy Designation

AZN

Product Launch

New Projects/Investments

AstraZeneca and Daiichi Sankyo's Enhertu has been granted Breakthrough Therapy Designation (BTD) by the US FDA for adult patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant treatment and a high risk of disease recurrence.
This marks the tenth BTD for Enhertu and was based on results from the DESTINY-Breast05 Phase III trial, which demonstrated impressive clinical benefit over the current standard of care.
The BTD is expected to accelerate the development and regulatory review of Enhertu, aiming to provide an important new treatment option to reduce recurrence risk and prevent progression to metastatic disease.

Dec 22, 2025, 12:18 PM

6-K

AstraZeneca's LATIFY Phase III Trial Fails to Meet Primary Endpoint

AZN

The LATIFY Phase III trial of ceralasertib in combination with Imfinzi (durvalumab) did not meet its primary endpoint of overall survival (OS) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
This trial focused on patients whose disease had progressed on or after prior immunotherapy and platinum-based chemotherapy.
The combination of ceralasertib and Imfinzi was generally well tolerated, with a safety profile consistent with the known profiles of each individual medicine and no new safety concerns identified.
AstraZeneca expressed disappointment with the result but affirmed its commitment to pioneering new medicines to improve outcomes for lung cancer patients.